Team

 Dr Martin Woodle is CEO of the  company.  Dr. Martin C. Woodle has  30 years experience in pharmaceutical research and development and currently is co-founder and President of VaxTecBio, developing advanced nanoparticle vaccine technology for infectious disease and cancer as well as Norwood Nano Tech developing gene-function reagents and therapeutics. Most recently Dr. Woodle co-founded Aparnabio, and previously founded Intradigm Corp. as CEO to commercialize Novartis Synthetic Gene Vector technology. He led financing of Intradigm of over $20 million by top tier venture funds including Frazier Healthcare Ventures, Alta Partners, MediBic, Genenfunds, and Novartis Venture Fund, and development of the first efficacious siRNA in primates and murine cancer models. 

Dr Kango is founder and president of the company. He has a 30 years  experience in wide variety of product and assay development. Worked as a  team leader in the development of Cat-GC platform (DARPA), Team leader  early lung cancer detection technology under CRADA with NIH. Developed  and patented technologies for SPR Platform Chips. Extensive experience in vaccine and biological developments  for infectious diseases.  More than 15 years of experience providing technology  services and implementation at HiTech to key clients in US on variety and diverse projects.      

Dr. Archibald J. Mixson is a faculty with   University of Maryland Medical   School  and is Board Certified Internist. Dr  Mixson is father of nano medicine and  drug delivery. He  has several  patents and has published  widely on  this subject.  His patented inventions include vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal  and other patented  inventions includeing  siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing  besides many other  land mark inventions.

Dr. Asif Qadri, MD, is a Cardiovascular Disease specialist practicing in Silver Spring, MD with 55 years of experience. Dr  Qadri is a world class well respected  cardiologist and has taught   cardiology seminars to residents at different programs. Dr Qadri is Founder and Director of MCC clinic  one of the  largest charitable Medical Clinic on east coast of USA. Clinic has provided services to more than 15,000 patients and around 100,000  patient encounters are recorded. Under his leadership clinic has been able to secure funding from  many prestigious organizations like Kaiser Permanente, Susan G. Komen Foundation, Healthcare Initiative Foundation, Maryland State and  Montgomery County. He has been honored by many local and national organizations.

Dr. Fazal  is an industry leader who served as Vice president of  several biotech and biopharma companies including Human Genome Sciences  worked as Senior Vice president at very senior level  and was part of the team raising 1.5 billion dollars.  Senior Vice President of Manufacturing Operations at Merrimack, Inc.. Senior Vice President of Manufacturing Operations at Merrimack, Inc and was responsible getting  FDA approval of a drug for Pancreatic cancer. He served as a senior director  at  Director of Biopharmaceutical Development and Manufacturing at Hoffmann-LaRoche, Inc in his early career. Recently he incepted  Advanced Bioanalytical Systems  which was sold  for an undisclosed amount of money.

Dr. Khan  is a Professor of Microbiology, Immunology and Tropical Medicine   at The George Washington University Washington, DC.  Prof Khan is an outstanding professor of vaccines, biologicals and  Immuno therapy. He has around one  hundred publications and book chapters. His group has been studying  development of CD8+ T cell immunity against parasitic infections for past 25 years and  through their pioneering work, Dr. Khan's laboratory demonstrated the role of CD8+ T cells, perforin-mediated cytotoxicity and cytokines in protection against the pathogen. Their research has further focused on the gut immune response against this pathogen, which is a highly understudied area. Dr Khan's  research interests also include  molecular mechanism of vaccine immunogenecity and efficacy. 

Dr Haji is a cardiology super specialist. Recently Chief of Cardiology Martinsburg, VA Medical Hospital , VA. Served in several medical programs as cardiology faculty in New York and Ohio. Dr Haji has keen interest in personalized medicine , its development, applications and future.